Francesca Zammarchi, PhDChief Scientific Officer at Myricx BioSpeaker
Profile
Dr. Francesca Zammarchi is Chief Scientific Officer at Myricx Bio, a UK/US biotechnology company developing a novel class of cytotoxic payloads for antibody–drug conjugates (ADCs) based on N-myristoyltransferase (NMT) inhibitors. She joined Myricx in October 2023 and leads the company’s scientific strategy and R&D execution as it advances next-generation ADC therapeutics.
Prior to Myricx, Dr. Zammarchi spent 10 years at ADC Therapeutics, most recently as Head of Preclinical Pharmacology, where she played a key role in the discovery and evaluation of new ADC programs and led preclinical pharmacology studies supporting portfolio progression.
Earlier in her career, she spent 9 years at Memorial Sloan Kettering Cancer Center, contributing to oncology research spanning cancer biology and translational science. She holds a PhD in Experimental and Molecular Oncology from the University of Pisa.
Agenda Sessions
From Discovery to Translation: Pre-Clinical Advancement of NMT Inhibitors as a Novel Payload Platform for ADC Development
, 08:20View Session